Infective endocarditis in pregnant women without intravenous drug use: a multicentre retrospective case series - Institut de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition Accéder directement au contenu
Article Dans Une Revue Journal of Antimicrobial Chemotherapy Année : 2022

Infective endocarditis in pregnant women without intravenous drug use: a multicentre retrospective case series

Pau Rello
Vincent Dubée
Christine Selton-Suty
Cristiane da Cruz Lamas
Francisco Nacinovich
  • Fonction : Auteur
Nahema Issa
Clémence Richaud

Résumé

Objectives: To describe the clinical features and outcomes of infective endocarditis (IE) in pregnant women who do not inject drugs. Methods: A multinational retrospective study was performed at 14 hospitals. All definite IE episodes between January 2000 and April 2021 were included. The main outcomes were maternal mortality and pregnancy-related complications. Results: Twenty-five episodes of IE were included. Median age at IE diagnosis was 33.2 years (IQR 28.3-36.6) and median gestational age was 30 weeks (IQR 16-32). Thirteen (52%) patients had no previously known heart disease. Sixteen (64%) were native IE, 7 (28%) prosthetic and 2 (8%) cardiac implantable electronic device IE. The most common aetiologies were streptococci (n = 10, 40%), staphylococci (n = 5, 20%), HACEK group (n = 3, 12%) and Enterococcus faecalis (n = 3, 12%). Twenty (80%) patients presented at least one IE complication; the most common were heart failure (n = 13, 52%) and symptomatic embolism other than stroke (n = 4, 16%). Twenty-one (84%) patients had surgery indication and surgery was performed when indicated in 19 (90%). There was one maternal death and 16 (64%) patients presented pregnancy-related complications (11 patients ≥1 complication): 3 pregnancy losses, 9 urgent Caesarean sections, 2 emergency Caesarean sections, 1 fetal death, and 11 preterm births. Two patients presented a relapse during a median follow-up of 3.1 years (IQR 0.6-7.4). Conclusions: Strict medical surveillance of pregnant women with IE is required and must involve a multidisciplinary team including obstetricians and neonatologists. Furthermore, the potential risk of IE during pregnancy should never be underestimated in women with previously known underlying heart disease.
Fichier principal
Vignette du fichier
Escola-Verge et al - 2022 - Infective endocarditis in pregnant women_JAC-2022-0428.R1-FINAL.pdf (128.88 Ko) Télécharger le fichier
Escolà-Vergé_Supplementary_Data.pdf (308.03 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03777460 , version 1 (21-09-2022)

Identifiants

Citer

Laura Escolà-Vergé, Pau Rello, Charles Declerck, Vincent Dubée, Fréderic Rouleau, et al.. Infective endocarditis in pregnant women without intravenous drug use: a multicentre retrospective case series. Journal of Antimicrobial Chemotherapy, 2022, ⟨10.1093/jac/dkac258⟩. ⟨hal-03777460⟩
118 Consultations
117 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More